BioXcel Therapeutics Inc. (BTAI)
1.87
0.02 (1.08%)
At close: Apr 25, 2025, 3:59 PM
1.90
1.64%
Pre-market: Apr 28, 2025, 09:17 AM EDT
1.08% (1D)
| Bid | 1.87 |
| Market Cap | 10.26M |
| Revenue (ttm) | 2.27M |
| Net Income (ttm) | -59.6M |
| EPS (ttm) | -23.51 |
| PE Ratio (ttm) | -0.08 |
| Forward PE | -0.11 |
| Analyst | Buy |
| Ask | 1.9 |
| Volume | 33,364 |
| Avg. Volume (20D) | 4,547,141 |
| Open | 1.87 |
| Previous Close | 1.85 |
| Day's Range | 1.82 - 1.90 |
| 52-Week Range | 1.29 - 43.12 |
| Beta | 0.64 |
About BTAI
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 8, 2018
Employees 37
Stock Exchange NASDAQ
Ticker Symbol BTAI
Analyst Forecast
According to 5 analyst ratings, the average rating for BTAI stock is "Buy." The 12-month stock price forecast is $48, which is an increase of 2467.81% from the latest price.
Stock ForecastsNext Earnings Release
BioXcel Therapeutics Inc. is scheduled to release its earnings on May 12, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+7.73%
BioXcel Therapeutics shares are trading higher aft...
Unlock content with
Pro Subscription
1 month ago
+22.99%
BioXcel Therapeutics shares are trading higher after the company announced it has reached 33% enrollment in its 200-patient SERENITY At-Home trial.
